Form4insider filings, from the source

SEC Form 4 · accession 0000947871-17-000581

Kala Pharmaceuticals, Inc. · KALA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
Samuel D Isaly
10% Owner · Other
ORBIMED ADVISORS LLC
10% Owner · Other
OrbiMed Capital GP VI LLC
10% Owner · Other
Period of report
Jul 25, 2017
Accepted (ET)
Jul 27, 2017 · 7:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479419

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F3,F4Jul 25, 2017C2,055,946—A2,055,946ISee Footnotes
Common StockF3,F4Jul 25, 2017P319,333$15.00A2,375,279ISee Footnotes

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Series C Preferred StockF3,F4,F1,F2—Jul 25, 2017C10,707,985D——Common Stock2,055,9460I

Explanation of responses

Remarks

In connection with the closing of the Issuer's initial public offering, which occurred on the same day as the transactions reported on this filing, the Reporting Persons will no longer be deemed to beneficially own greater than 10% of the outstanding shares of the Issuer.